Wayne Jonas, MD, executive director of Samueli Integrative Health Programs at H&S Ventures, discusses what new therapies are emerging in the world of pain management.
Transcript:
Are there any newer therapies for pain on the horizon that you are keeping an eye on?
Well, there's a number of them and the evidence is growing more and more for these. For those that are interested in, in kind of keeping up with what is reaching the level of sufficient evidence to consider for your own practice. I would urge you to look at the VA's Whole Health website, where they have a list of currently recommended approaches for chronic illness many of which are for chronic pain.
[Some] CME [continuing medical education] courses list current approaches that now have sufficient evidence to consider for everybody to put into these areas.
I know there are also increasing approaches to chronic pain with new drugs, for example, ketamine. But ketamine has great addictive potential and it can be used only cautiously in certain types of patients, chronic regional pain syndrome, for example, and some types of neuropathy. It needs to be used carefully. Most of the time has to be given [intravenous] in the office.
So, there these are new therapies that are of interest, but they need to be used appropriately based on good evidence and integrated with the leading components for chronic pain management that impact patients in the long run, which are the behavior, lifestyle, and nonpharmacological approaches.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More